EP Patent

EP3472134B1 — Process for preparing compounds useful as intermediates for the preparation of raltegravir

Assigned to Pharmathen SA · Expires 2021-10-20 · 5y expired

What this patent protects

Patent listed against raltegravir-potassium.

Drugs covered by this patent

raltegravir-potassium (RALTEGRAVIR POTASSIUM)

Patent Metadata

Patent number: EP3472134B1
Jurisdiction: EP
Classification: —
Expires: 2021-10-20
Drug substance claim: No
Drug product claim: No
Assignee: Pharmathen SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.